Drug development by leveraging proven compounds
Methylation Sciences Inc (MSI), based in Canada, is a company focused on developing pharmaceuticals based on molecules which are proven to be clinically effective but which have yet to be exploited in major pharmaceutical markets.
MSI is actively developing proprietary formulations of naturally-occurring S-Adenosyl Methionine (SAMe) as a stand-alone pharmaceutical product and/or in combination (adjunctive) with current therapies for the treatment of major depressive disorder.
Efficacy and safety profile
A long record of clinical use and large body of credible, supporting research indicates that SAMe is safe, well tolerated and clinically effective. Our proprietary formulations of SAMe exhibit a broad range of benefits, including extended release, improved PK profile and reduced dosing requirements to achieve a therapeutic response.